<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0022">
 <label>22</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Chen</surname>
    <given-names>C-N</given-names>
   </name>, 
   <name name-style="western">
    <surname>Lin</surname>
    <given-names>CPC</given-names>
   </name>, 
   <name name-style="western">
    <surname>Huang</surname>
    <given-names>K-K</given-names>
   </name>, 
   <etal>et al.</etal>
  </person-group>
  <article-title>Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3'-digallate (TF3)</article-title>. 
  <source>Evid Based Complement Alternat Med</source>
  <year>2005</year>;
  <volume>2</volume>:
  <fpage>209</fpage>–
  <lpage>15</lpage>.
  <pub-id pub-id-type="pmid">15937562</pub-id>
 </mixed-citation>
</ref>
